ERBB2 and breast cancer: Although the advent of HER2 directed therapies has markedly enhanced overall survival rates, between 30 % and 50 % of individuals with HER2-positive BC ultimately experience intracranial metastatic spread, rendering central nervous system (CNS) progression a leading contributor to illness and death in this patient population (2–4).